Category: KFF Health News’ ‘What The Health?’

The Abortion Pill Goes Back to Court

A three-judge appeals court panel heard testimony this week about revoking the FDA’s 22-year-old approval of a key pill used in medication abortion and miscarriage management. The judges all have track records of siding with abortion foes. Meanwhile, as the standoff over raising the federal debt ceiling continues in Washington, a major sticking point is whether to impose work requirements on recipients of Medicaid coverage. Victoria Knight of Axios, Rachel Roubein of The Washington Post, and Sandhya Raman of CQ Roll Call join KFF Health News chief Washington correspondent Julie Rovner to discuss these issues and more.

The Crisis Is Officially Ending, but Covid Confusion Lives On

The public health emergency declaration for covid-19 ends May 11, ushering in major changes in how Americans can access and pay for the vaccines, treatments, and tests particular to the culprit coronavirus. But not everyone will experience the same changes, creating a confusing patchwork of coverage — not unlike health coverage for other diseases. Meanwhile, outside advisers to the FDA formally recommended allowing a birth control pill to be sold without a prescription. If the FDA follows the recommendation, it would represent the first over-the-counter form of hormonal contraception. Margot Sanger-Katz of The New York Times, Tami Luhby of CNN, and Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico join KFF Health News’ Julie Rovner to discuss these issues and more. Plus for “extra credit” the panelists suggest health policy stories they read this week they think you should read, too.

Health Programs Are at Risk as Debt Ceiling Cave-In Looms

A warning from the Treasury Department that the U.S. could default on its debt as soon as June 1 has galvanized lawmakers to intervene. But there is still no obvious way to reconcile Republican demands to slash federal spending with President Joe Biden’s demand to raise the debt ceiling and save the spending fight for a later date. Meanwhile, efforts to pass abortion bans in conservative states are starting to stall as some Republicans rebel against the most severe bans. Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico, Rachel Cohrs of Stat, and Alice Miranda Ollstein of Politico join KFF Health News chief Washington correspondent Julie Rovner to discuss these issues and more.

Dancing Under the Debt Ceiling

House Republicans passed their plan to raise the nation’s debt ceiling, along with major cuts to health (and other domestic) programs. Unlikely to become law, it calls for new work requirements for adults on Medicaid. Meanwhile, state efforts targeting trans people bear a striking resemblance to the fight against abortion rights. Jessie Hellmann of CQ Roll Call, Shefali Luthra of The 19th, and Sarah Karlin-Smith of the Pink Sheet join KFF Health News chief Washington correspondent Julie Rovner to discuss these issues and more. Also this week, Rovner interviews Renuka Rayasam, who reported the latest KFF Health News-NPR “Bill of the Month” feature, about a specialist’s demand to be paid as much as $15,000 before treating a woman’s serious pregnancy complication.

Will They or Won’t They (Block the Abortion Pill)?

The Supreme Court is considering the future of the abortion pill mifepristone, after GenBioPro sued the FDA over limitations that effectively block generic production of the drug, a major part of the market. Congress is considering proposals that would impose Medicaid work requirements, crack down on pharmacy benefit managers, and more. And President Joe Biden moved to expand health coverage to young immigrants known as “Dreamers.” Rachel Cohrs of Stat, Sandhya Raman of CQ Roll Call, and Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico join KFF Health News’ Mary Agnes Carey to discuss these issues and more.

The Confusing Fate of the Abortion Pill

The legality and availability of the abortion pill mifepristone is in question after a federal judge in Texas canceled the FDA’s approval of the first drug used in the two-drug medication abortion regimen. A 5th Circuit Court of Appeals panel overruled that decision in part, saying the pill should remain available, but only under the onerous restrictions in place before 2016. Meanwhile, another federal judge in Washington state issued a ruling in a separate case that conflicts with the Texas decision, ordering the FDA not to roll back any of its restrictions on the drug. Victoria Knight of Axios, Shefali Luthra of The 19th, and Sarah Karlin-Smith of the Pink Sheet join KFF Health News chief Washington correspondent Julie Rovner to discuss these issues and more.